Management of small cell carcinoma of the lung. Therapy, staging, and biochemical markers

Martin D. Abeloff, David S. Ettinger, Stephen B. Baylin, Tapan Hazra

Research output: Contribution to journalArticlepeer-review

Abstract

A chemotherapeutic regimen consisting of BCNU, cyclophosphamide, vincristine, and procarbazine was evaluated in 43 patients with small cell carcinoma of the lung. The majority of patients received radiation therapy to the primary tumor, but chemotherapy alone was utilized in a group of patients with widely disseminated disease. In addition to thorough staging with radioisotope scans and bone marrow biopsies, a study of calcitonin and histaminase as biochemical markers was performed. The BCVP chemotherapy resulted in a complete and partial response rate of 53% when given alone or in conjunction with radiotherapy. The survival data are preliminary, but the complete responders do have a statistically significant better survival (mean of +295 days) than the partial responders and nonresponders. Hypercalcitonemia was not detected in our patients, but elevated histaminase activity was found in eight of 24 patients with small cell carcinoma and in only one of 19 patients with squamous and large cell carcinoma.

Original languageEnglish (US)
Pages (from-to)1394-1401
Number of pages8
JournalCancer
Volume38
Issue number3
DOIs
StatePublished - Sep 1976

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of small cell carcinoma of the lung. Therapy, staging, and biochemical markers'. Together they form a unique fingerprint.

Cite this